AHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke. Version: 13 March 2017
|
|
- Edwina Payne
- 5 years ago
- Views:
Transcription
1 AHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke Version: 13 March 2017
2 Introduction This business case template has been created so that each organisation can assess the potential for improvements in the identification and management of Atrial Fibrillation (AF) in four key areas: Diagnosis of AF: Detection Gap Identification of those at high risk of stroke (CHA 2 DS 2 -VASc): Protection Gap 1 (no risk assessment) Initiation of anticoagulant therapy in line with national guidelines: Protection Gap 2 (eligible and untreated) Maintenance of adequate anticoagulation: Perfection Gap User modifications: The AHSN or CCG can be selected on Sheet 2: Detection Gap
3 The business model cost analysis Using either the default numbers provided in the model or the numbers provided by the user, the business model evaluates the identified management gaps and calculates: The clinical impact (number of preventable strokes / risk of bleed) potentially achieved by addressing each management gap The total potential cost investment to address each gap The overall estimated cost impact for addressing each opportunity over a one, two and three year period This generates an automatic business case report that provides a summary of the cost impact and cost savings for each management gap User modifications: The user can modify the planned interventions and their expected impact on the number of people with AF treated with an anticoagulant on Sheets 7 and 8: Planned Interventions
4 Data sources: Clinical and cost inputs The business case model has been created using publically available primary practice data, as well as published data inputs: Quality Outcomes Framework (QOF) AF indicators (2015/2016 datasets) using CHA 2 DS 2 -VASc score are the principal AF management comparators (see later slide for list of QOF AF indicators) The predicted AF population is calculated using the age-sex specific data from the National Cardiovascular Intelligence Network (NCVIN) predictive model, and aggregated July 2016 GP practice demographics (previous calculations were based on 2013 data) Current AF-related stroke rates are as reported by the Sentinel Stroke National Audit Programme (SSNAP) (April 2015-March 2016 datasets) Data used in the TA256 and TA249 technology appraisals and NICE CG180 costing template have been used as the default clinical (risk of stroke and risk of bleed) and cost inputs in the cost impact analysis. More recent meta-analysis (such as Ruff et al, 2014) or local data can be substituted in the model Anticoagulant treatment data was taken from from the NHS Business Services Authority Medicines Optimisation CCG Dashboard (April 2016-June 2016)
5 Click Data sources: to edit Clinical Master inputs title style User modifications: Clinical assumptions can be modified for the local situation on Sheet 9: Clinical inputs Clinical input variables: Annual risk of stroke: 1) untreated, 2) treated with warfarin, 3) treated with Novel Oral Anticoagulants (NOAC) Annual risk of major bleed: 1) untreated, 2) treated with warfarin, 3) treated with NOAC The assumptions included in the model are based on the AF data used in the TA256 and TA249 technology appraisals and NICE CG180 costing template.
6 Click Data sources: to edit Cost Master inputs title style User modifications: Cost assumptions can be modified for the local situation on Sheet 11: Cost inputs Cost input variable: Year 1 per patient cost of stroke care Year 2+ per patient cost of stroke care (Default values taken from Youman et al (2003) used in NICE CG180 /TA256) Cost of a major bleed (Default values as used in NICE CG180 and TA256) Cost of screening for AF (per patient screened) (Default values are from Hobbs et al (2005) using the mid-point value and applying the Hospital and Community Health Services (HCHS) inflator) Cost of treatment (Warfarin and NOAC) Warfarin (drug cost + screening) based on NICE CG180 and TA256 NOAC price based on 2016 NHS prices, weighted by use
7 Click Data sources: to edit Planned Master interventions title style User modifications: At the end of the Excel work sheet the user can input free text to describe their planned current interventions for each management gap. This information will then be used to help populate the business case template. (Users can also add their current activities in a separate sheet if they would like to include this in the report for comparison) The anticipated impact and timelines for the planned interventions can be changed on Sheets 7 and 8: Planned Interventions This enables the user to modify the potential level of correction that could be anticipated for each gap: A default correction level of 50% is set for the Detection Gap A default correction level of 90% is set for Protection Gap 1 A default correction level of 80% is set for the Protection Gap 2 and the Perfection Gap
8 Click Data sources: to edit Anticoagulation Master title treatment style strategy User modifications: The default cost analysis uses the current NOAC and warfarin prescribing patterns in the calculations. This ratio can be modified on Sheet 12: Treatment strategy. The ratio can be modified for years 1, 2 and 3 Projected % NOAC use can be changed for both patients inadequately anti-coagulated and new patients NOTE: The business case will not model the impact of switching therapy for existing stable patients for this purpose you should use the NICE costing model accompanying CG180. If you would like to do a comparison between different treatment approaches we recommend running the model each time and creating a separate report for each alternative approach. The two (or more) reports can then be combined and reported in Word format, as required.
9 Detection Gap Summary Total population in and have been obtained by aggregating individual GP practice list sizes for each organisation. QOF AF001 register 2015/2016 datasets are used for patients on the AF register in each GP practice and compared with 2014/2015 datasets The predicted AF population is calculated using the age-sex specific data from the NCVIN predictive model, using July 2016 GP practice demographics Data on AF-related stroke are as reported by the April 2015-March 2016 Sentinel Stroke National Audit Programme (SSNAP) reporting
10 Click Detection to edit Gap Summary: Master title User modifications style User modifications: No data modification are permitted on the Detection Gap calculations but it is recommended that the predicted AF population data are reviewed in comparison with the ethnic mix and underlying disease profile when applied to specific regional populations populations compared with the NCVIN benchmark population. The GP practice lists show that the proportion of the population >65 years varies from <10% in inner cities up to >25% in some rural and coastal areas. These numbers should therefore be seen as indicative rather than absolute. To adjust the Detection Gap the potential impact (% increase in number of patients likely treated) can be altered on Sheet 7: Planned Interventions
11 Protection Gap 1 (no risk assessment) Summary QOF AF /2016 denominator and exceptions are combined to provide the number of patients requiring a risk assessment This is compared with the QOF AF /2016 target achieved data set to calculate the number of missing risk assessments The number of potential patients eligible for treatment is then calculated using the assumption from NICE CG180 that 84.2% of patients have a CHA 2 DS 2 -VASc score 2 User modifications: No user modifications permitted
12 Protection Gap 2 (eligible and untreated) Summary QOF AF /2016 denominator and exceptions are combined to provide the number of patients currently considered eligible for anticoagulation This number is compared with the QOF AF /2016 target achieved data set to calculate number of patients eligible but untreated with anticoagulant User modifications: No user modifications permitted
13 Perfection Gap Summary QOF AF /2016 target achieved data set provides the number of patients currently treated An analysis of practice level prescribing data provides the anticipated treatment levels with NOAC or warfarin (assumption: 90% NOACs are for AF; remaining patients are assumed to receive warfarin)* Assumptions data are inputted for the current effectiveness of anticoagulation (Perfection gap) *See the following slide for further detail of NOAC and warfarin treatment calculations User modifications: The user can modify the assumptions around the current effectiveness for NOAC and warfarin treatment based on regional knowledge in order to modify the anticipated Perfection gap.
14 Anticoagulant calculations In relation to anticoagulant therapy, the proportion of anticoagulated patients on warfarin versus NOACs were identified from the NHS Business Services Authority Medicines Optimisation CCG Dashboard, which is based on an analysis of prescribing for the period April 2016-June The proportion of patients in each CCG on NOAC therapy identified from this analysis were applied to the number of anticoagulated patient, derived from QOF AF007, to arrive at the number of patients receiving either NOAC or warfarin.
15 QOF AF indicators QOF target AF001: Each GP practice maintains a register of patients with AF QOF target AF006: The percentage of patients with AF in whom stroke risk has been assessed using the CHA 2 DS 2 -VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS 2 or CHA 2 DS 2 -VASc score of 2 or more) QOF target AF007: In those patients with AF with a record of a CHA 2 DS 2 -VASc score of 2 or more, the percentage of patients who are currently treated with anti-coagulation drug therapy
16 Data references QOF data: NHS Digital. Quality and Outcomes Framework (QOF) Prevalence, achievements and exceptions, cardiovascular group at GP practice level. Available at: Accessed 16/12/16 GP practice population and demographic data: NHS Digital. Numbers of patients registered at a GP practice. 1/7/2016 GP registered patients. Available at: Accessed 16/12/16 Prescribing data: NHS Digital. GP Practice prescribing presentation-level data (July 2015-June 2016). Available at: (1 file per month). Accessed 16/12/16 NCVIN prevalence rates: Public Health England: National Cardiovascular Intelligence Network. Atrial fibrillation prevalence estimates. Available at: Accessed 16/12/16 Public Health England: National Cardiovascular Intelligence Network. Atrial fibrillation prevalence estimates. Technical document for sub-national English atrial fibrillation prevalence estimates: application of age-sex rates in a Swedish region to the English population. Available at: Accessed 16/12/16
17 Key References Hobbs F, Fitzmaurice D, Mant J et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:1-74 National Institute for Health and Care Excellence. Atrial fibrillation: management - Clinical guideline (CG180) - costing template. June Available at: (Accessed December 2016) National Institute for Health and Care Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) - costing template. March Available at: (Accessed December 2016) National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249) - costing template. March Available from: (Accessed November 2016) Norberg J, Backstrom S, Jansson J-H, Johansson L. Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data. Clin Epidemiol. 2013: 5: Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin inpatients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: Statistics Sweden. Foreign born persons by region. Available at: BE BE0101 BE0101E/UtrikesFoddaTotNK/?r xid=b2913b8e-bdfa-4451-ba93-2d6f9b77d03c Accessed 16/12/16 Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003;21 Suppl1:43-50
Tackling atrial fibrillation the health economics evidence
Tackling atrial fibrillation the health economics evidence Professor Gary Ford,CBE Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals
More informationThat the Single Commissioning Board supports the project outlined in this report and proceeds as described.
Report to: SINGLE COMMISSIONING BOARD Date: 26 September 2017 Officer of Single Commissioning Board Subject: Report Summary: Recommendations: Jessica Williams Interim Director of Commissioning ATRIAL FIBRILLATION
More informationAlison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG
Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG Commissioning is the set of linked activities required to assess the healthcare needs of a population, specify the services
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationAgenda Item No. 8a SERVICE SPECIFICATION. 1. Introduction:
SERVICE SPECIFICATION Agenda Item No. 8a Service Specification No. Service Atrial Fibrillation Audit patient reviews Commissioner Lead Caroline Davidson Period 1 st September to 31 st March 2017 Date of
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationrequesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group
October 2015 Our Ref: FOI.15.ASH0149 requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group Original Request Survey attached. Question 1: Between 1 July 2014 and
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationRhona Maclean
An early evaluation of the impact of the North Trent policy regarding the use of Non-Vitamin K antagonists for SPAF in a secondary care anticoagulation clinic Rhona Maclean Rhona.maclean@sth.nhs.uk Risk
More informationCosting statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September
More informationADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationGRASP-AF- The National Picture. Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012
GRASP-AF- The National Picture Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012 Outline AF and stroke Objective Management of stroke risk Stroke risk
More informationCommissioning for value focus pack
Commissioning for value focus pack Clinical commissioning group: NHS MILTON KEYNES CCG Focus area: Cardiovascular disease (CVD) pathway Version 2 June 2014 Contents 1. Background and context About the
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationAudit+ Atrial Fibrillation Module (beta V2.1) quick start guide To Review Therapy
Save A Stroke Campaign 2016 Quality Improvement Cardiff & Vale UHB & Public Health Wales Audit+ Atrial Fibrillation Module (beta V2.1) quick start guide To Review Therapy 1 Quality Improvement [AUDIT+
More informationOptimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire
Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire Dr Chris Arden GP, Chandlers Ford GPSI Cardiology, Southampton West Hampshire CCG Cardiovascular
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationQuality Improvement Tool Instruction Guide GRASP-AF
Quality Improvement Tool Instruction Guide GRASP-AF The GRASP-AF quality improvement tool has been developed by PRIMIS and delivered in partnership with NHS England. Prepared by PRIMIS September 2017 The
More informationUsing the NIH Collaboratory's and PCORnet's distributed data networks for clinical trials and observational research - A preview
Using the NIH Collaboratory's and PCORnet's distributed data networks for clinical trials and observational research - A preview Millions of people. Strong collaborations. Privacy first. Jeffrey Brown,
More informationThe case against structured screening for Atrial Fibrillation in General Practice
The case against structured screening for Atrial Fibrillation in General Practice THE CASE AGAINST STRUCTURED SCREENING FOR ATRIAL FIBRILLATION IN GENERAL PRACTICE or the PCCJ conference Nov 2015 r Ivan
More informationOptimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire
Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire Dr Chris Arden GP, Chandlers Ford GPSI Cardiology, Southampton West Hampshire CCG Cardiovascular
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationCQC Insight. NHS GP practices Indicators and methodology
CQC Insight NHS GP practices s and methodology June 2017 Contents Introduction... 3 Background information on CQC Insight reports... 4 Displaying proportions as percentages... 5 Suppression rules... 5
More informationReview of devices for early AF detection Nadya Hamedi Primary Care cardiovascular pharmacist Health innovation Network
Review of devices for early AF detection Nadya Hamedi Primary Care cardiovascular pharmacist Health innovation Network n.hamedi@nhs.net HRC 2016 The ICC Birmingham UK 9-12 October 2016 PAN London AF Improvement
More informationCLINICAL AUDIT. Renal Function Testing in People. Taking Dabigatran
CLINICAL AUDIT Renal Function Testing in People Taking Dabigatran Valid to December 2017 bpac nz better medicin e Background Dabigatran is an oral anticoagulant used primarily to prevent stroke in people
More informationGetting Serious About CVD Prevention What does this mean for Primary Care?
Getting Serious About CVD Prevention What does this mean for Primary Care? Dr Matt Kearney GP and National Clinical Director for Cardiovascular Disease Prevention NHS England and Public Health England
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationSMASH! The Salford Medication Safety Dashboard. Richard Williams. NIHR Greater Manchester Patient Safety Translational Research Centre
NIHR Greater Manchester Patient Safety Translational Research Centre SMASH! The Salford Medication Safety Dashboard Richard Williams This presentation summarises independent research funded by the NIHR
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Thank you for agreeing to give us a statement on your organisation s view of the technology and the way
More informationGetting serious about preventing cardiovascular disease
Getting serious about preventing cardiovascular disease Southwark s Experience Professor Kevin Fenton Director of Health and Wellbeing, London Borough of Southwark February 2018 Twitter: @ProfKevinFenton
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial Response
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationStroke Prevention & Atrial Fibrillation. Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015
Stroke Prevention & Atrial Fibrillation Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015 Learning Outcomes What is Atrial Fibrillation? Why is Atrial Fibrillation important? What causes
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationA New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG
A New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG Dr Rosie Heath GP Principal Church view medical centre and GPwSI Western locality Cardiology
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationDEMENTIA PREVALENCE CALCULATOR
DEMENTIA PREVALENCE CALCULATOR Guidance on using the Dementia Prevalence Calculator Introduction In March 2012 the Prime Minister published his challenge on dementia 1 which set out an ambitious programme
More informationCVD: Primary Care Intelligence Packs
CVD: Primary Care Intelligence Packs NHS High Weald Lewes Havens CCG June 2017 Version 1 Contents 1. Introduction 3 2. CVD prevention The narrative 11 The data 13 3. Hypertension 4. Stroke 5. Diabetes
More informationNOACs in AF. Dr Fiona Stewart. Auckland Heart Group and Auckland DHB
NOACs in AF Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACS for AF True/False All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF NOACS are more effective than warfarin
More informationAccess from the University of Nottingham repository:
Holt, Tim A. and Dalton, Andrew and Marshall, Tom and Fay, Matthew and Qureshi, Nadeem and Kirkpatrick, Susan and Hislop, Jenny and Lasserson, Daniel and Kearley, Karen and Mollison, Jill and Yu, Ly-Mee
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Hypertension QOF indicator area: Hypertension Date: July 2013
More informationResource impact report: Eating disorders: recognition and treatment (NG69)
Resource impact report: Eating disorders: recognition and treatment (NG69) Published: May 2017 Summary This report looks at the resource impact of implementing NICE s guideline on eating disorders: recognition
More informationNHS England Getting Serious About Prevention
NHS England Getting Serious About Prevention Dr Matt Kearney GP and National Clinical Director for Cardiovascular Disease Prevention NHS England and Public Health England The NHS needs a radical upgrade
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationAtrial Fibrillation Collaborative. Thursday 7 May 2015
Atrial Fibrillation Collaborative Thursday 7 May 2015 Welcome and introductions Peter Carpenter KSS AHSN Nicky Jonas SEC CVD SCN AF Project Support KSS Academic Health Science Network & South East Cardiovascular
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationNational Diabetes Treatment and Care Programme
National Diabetes Treatment and Care Programme Introduction to and supporting documentation for VALUE BASED TRANSFORMATION FUNDING SITE SELECTION December 2016 1 Introduction and Contents The Planning
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationUpdates in Atrial Fibrillation
Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000
More informationQuality and Outcomes Framework Programme NICE cost impact statement July Indicator area: Osteoporosis - fragility fracture
Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Osteoporosis - fragility fracture Indicators NM29: The practice can produce a register of patients: 1. Aged
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More information18/09/2012. Dr. Khalid Khan Consultant Cardiologist BCUHB. Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham
Dr. Khalid Khan Consultant Cardiologist BCUHB Oral Anticoagulation Update Day 12 th September 2012 University of Birmingham 1 NICE vs. Local Guidance NICE says no We say no NICE says yes We say no NOACs
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationApixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation STA REPORT This report was commissioned by the NIHR HTA Programme as project number 11/49 Page
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationGLORIA -AF REGISTRY PROGRAMME
GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationBMJ Open. Cardiovascular medicine. Secondary Subject Heading: General practice / Family practice, Pharmacology and therapeutics
Primary Care Atrial Fibrillation Service: Outcomes from Consultant-led anticoagulation assessment clinics in the Primary Care setting Journal: BMJ Open Manuscript ID: bmjopen-0-00 Article Type: Research
More informationNovel Anticoagulants: Emerging Evidence
18/10/2016 Topics: Novel Anticoagulants: Emerging Evidence Dr Matthew Swale Electrophysiologist Genesis Care NOAC Novel Oral Anti Coagulant Now Non-Vit K Oral Anti Coagulant DOAC Direct Oral Anti Coagulant
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationHow effective are national strategies for getting evidence into practice?
How effective are national strategies for getting evidence into practice? Dr Gillian Leng Deputy Chief Executive, NICE Areas to cover Getting NICE guidance into practice Challenges National strategy Impact
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationQOF (England): clinical indicators
QOF 2015 16 (England): clinical indicators Here is a quick summary of the planned changes for QOF in England for 2015 16. This covers only the clinical aspects of QOF, as you might need them in the consultation,
More informationPeri-cardioversion and peri-ablation anticoagulation. Giuseppe Patti Campus Bio-Medico University of Rome
Peri-cardioversion and peri-ablation anticoagulation Giuseppe Patti Campus Bio-Medico University of Rome What 2016 ESC guidelines recommend Causes of TE events after cardioversion 1 Preexisting LA thrombosis
More informationCVD: Primary Care Intelligence Packs
CVD: Primary Care Intelligence Packs NHS South Tyneside CCG June 2017 Version 1 Contents 1. Introduction 3 2. CVD prevention The narrative 11 The data 13 3. Hypertension 4. Stroke 5. Diabetes 6. Kidney
More informationOptimising Hypertension Management Clair Huckerby Pharmaceutical Adviser- Medicines Optimisation Lead
Optimising Hypertension Management Clair Huckerby Pharmaceutical Adviser- Medicines Optimisation Lead Pharmaceutical Public Health Team The Office of Public Health and Dudley CCG Dudley - doing things
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationAtrial fibrillation: current approaches to management
DRUG REVIEW n Atrial fibrillation: current approaches to management Upasana Tayal MA, MRCP and Robert Greenbaum BSc, MD, FRCP, FESC, FACC Atrial fibrillation is the commonest arrhythmia and GPs have an
More informationAtrial fibrillation detection and management. Professor Lis Neubeck Head of Theme Long Term Conditions
Atrial fibrillation detection and management Professor Lis Neubeck Head of Theme Long Term Conditions Atrial fibrillation Most common cardiac arrhythmia Symptoms range from severely debilitating to none
More informationAtrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency
Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation
More informationTechnology appraisal guidance Published: 23 September 2015 nice.org.uk/guidance/ta355
Edoxaban for preventing enting stroke and systemic embolism in people with non- valvular atrial fibrillation Technology appraisal guidance Published: 23 September 2015 nice.org.uk/guidance/ta355 NICE 2015.
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationExternal Validity of the ARISTOTLE Trial in Real-Life Atrial Fibrillation Patients
ORIGINAL RESEARCH ARTICLE External Validity of the ARISTOTLE Trial in Real-Life Atrial Fibrillation Patients Lovisa H agg, Cecilia Johansson, Jan-Hakan Jansson & Lars Johansson Skelleftea Research Unit,
More informationNHS Rotherham Clinical Commissioning Group
NHS Rotherham Clinical Commissioning Group Operational Executive: 2 nd November 2015 Governing Body: 4 th November 2015 Review of Stroke Care Pathway GP Lead: Dr Phil Birks Lead Executive: Keely Firth
More informationCardiovascular disease profile - Heart disease. NHS Wirral CCG. June 2017
Cardiovascular disease profile - Heart disease June 217 Background This chapter of the Cardiovascular disease profiles focuses on coronary heart disease (CHD) and heart failure and is produced by the National
More informationDOAC support programme. engage supported self-care
DOAC support programme engage supported self-care changes in anticoagulation therapy Managing patients receiving anticoagulation (AC) therapy effectively and consistently can be challenging. Direct oral
More informationEffective information and learning from data the East London Approach
Effective information and learning from data the East London Approach Dr Kambiz Boomla GP and Clinical Senior Lecturer Queen Mary University of London and Clinical IT lead for east London CCGs Dr John
More informationCardiovascular disease profile
Cardiovascular disease profile Heart disease Background This chapter of the Cardiovascular disease profiles focuses on coronary heart disease (CHD) and heart failure and is produced by the National Cardiovascular
More informationNHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation
1 NHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation Atrial fibrillation (AF) affects about 1.2% of the population in the United Kingdom and accounts
More informationA Guide to AF within the Cardiovascular Disease Outcomes Strategy
A Guide to AF within the Cardiovascular Disease Outcomes Strategy Registered Charity No. 1122442 1 Foreword Through my experience as a Member of Parliament, Chair of the All-Party Parliamentary Group on
More informationPrimary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant
More informationEconomic Impact Evaluation Case Study: AliveCor Kardia Mobile
NHS Innovation Accelerator Economic Impact Evaluation Case Study: AliveCor Kardia Mobile 1. BACKGROUND The AliveCor Kardia Mobile ECG (Kardia Mobile) is a portable single-channel cardiac event recorder
More informationSUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL
SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 1/17 QOF ID 17/18 QOF ID NICE ID Indicator wording
More information